환자표본자료를 이용한 간이식 환자의 의료이용 특성 및 의료비용 분석
Analysis of Medical Use and Costs of Liver Transplant Patients Using National Patients Sample Data
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Patients experience significant differences in aspects of mortality, quality of life, and costs between during the year of receiving liver transplant (LT) and the subsequent years (post-LT). This study aimed to estimate the medical utilization and cost of LT for patients compared to post-LT patients by using a recent National Patient Sample (NPS) data provided by the Korean Health Insurance Review and Assessment Service (HIRA). Methods: This study used a subset of the 2015 HIRA-NPS. Patient claims data that included Z944 (Korean Standard Classification of Diseases code for LT status) were selected. Within the selected data, LT patients were identified based on whether the national health insurance number code of Q80 (procedure code for LT surgery) was included, and they were compared to post-LT patients. Results: In the analysis, 330 patients were included. The average cost per patient was 90,066±36,959 thousand KRW and 10,557±9,668 thousand KRW for LT and post-LT patients, respectively. Especially, LT patients’ costs for injection/procedure, surgery/treatment, and examination were higher than other costs, being 35,983±18,115 thousand KRW, 28,246±9,408 thousand KRW, and 12,131±6,604 thousand KRW, respectively. For inpatients, the average number of hospitalized days was 63.5±66.0 days for LT patients and 22.3±35.1 days for post-LT patients. Conclusion: Compared to postLT patients, LT patients had higher costs, especially for injection/procedure, surgery/treatment, and examination. Additionally, the LT group had longer hospitalization duration and higher costs for their hospital admission, whereas they did not show a significant difference in number of visits and medical costs for outpatient-care.
Abstract
Background: Patients experience significant differences in aspects of mortality, quality of life, and costs between during the year of receiving liver transplant (LT) and the subsequent years (post-LT). This study aimed to estimate the medical utilization and cost of LT for patients compared to post-LT patients by using a recent National Patient Sample (NPS) data provided by the Korean Health Insurance Review and Assessment Service (HIRA). Methods: This study used a subset of the 2015 HIRA-NPS. Patient claims data that included Z944 (Korean Standard Classification of Diseases code for LT status) were selected. Within the selected data, LT patients were identified based on whether the national health insurance number code of Q80 (procedure code for LT surgery) was included, and they were compared to post-LT patients. Results: In the analysis, 330 patients were included. The average cost per patient was 90,066±36,959 thousand KRW and 10,557±9,668 thousand KRW for LT and post-LT patients, respectively. Especially, LT patients’ costs for injection/procedure, surgery/treatment, and examination were higher than other costs, being 35,983±18,115 thousand KRW, 28,246±9,408 thousand KRW, and 12,131±6,604 thousand KRW, respectively. For inpatients, the average number of hospitalized days was 63.5±66.0 days for LT patients and 22.3±35.1 days for post-LT patients. Conclusion: Compared to postLT patients, LT patients had higher costs, especially for injection/procedure, surgery/treatment, and examination. Additionally, the LT group had longer hospitalization duration and higher costs for their hospital admission, whereas they did not show a significant difference in number of visits and medical costs for outpatient-care.
참고문헌 (37)
- White Paper on Liver Diseases in Korea, "The Korean Association for the Study of the Liver", ~ (2013)
- 김명수, "간장 응급도 기준 개선방안 연구: 한국형 멜드시스템의 학술적 배경", Clinical Transplantation and Research, 30(2), pp.51~58 (2016), 대한이식학회
- Lim Y-S, "Acute liver failure in Korea: etiology, prognosis and treatment", Korean J Hepatol, 16(1), pp.5~18 (2010)
- Lee HJ, "Liver Transplantation in Liver Cirrhosis", CMH, 12(20), pp.85~89 (2006)
- "Guidance on organ transplant management"[URL]
- "Statistics of Organ Transplantation Cases"[URL]
- "Clinical Guideline for liver Cirrhosis: Ascites and other complications"[URL]
- "Healthcare Bigdata Hub"[URL]
- Chhatwal J, "Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States", Ann Intern Med, 162(6), pp.397~406 (2015)[DOI]
- Cure S, "Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients", J Viral Hepat, 22(11), pp.882~889 (2015)[DOI]
- Leleu H, "Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C", J Viral Hepat, 22(4), pp.376~383 (2015)[DOI]
- Liu S, "Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis", Ann Intern Med, 161(8), pp.546~553 (2014)[DOI]
- Najafzadeh M, "Cost-effectiveness of novel regimens for the treatment of hepatitis C virus", Ann Intern Med, 162(6), pp.407~419 (2015)[DOI]
- Petta S, "Cost-effectiveness of sofosbuvirbased triple therapy for untreated patients with genotype 1 chronic hepatitis C", Hepatology, 59(5), pp.1692~1705 (2014)[DOI]
- Pfeil AM, "Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in swiss patients with chronic hepatitis C", PLoS One, 10(5), pp.e0126984~ (2015)[DOI]
- Saab S, "Cost-effectiveness analysis of sofosbuvir plus peginterferon", ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection, 2014, pp.40(6), 657~675
- Ke W, "Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China", Hepatol Int, 10(6), pp.924~936 (2016)[DOI]
- Wu B, "Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis", Value Health, 13(5), pp.592~600 (2010)[DOI]
- Zhang C, "Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China", Clin Drug Investig, 35(3), pp.197~209 (2015)
- San Miguel R, "Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C", Gut, 64(8), pp.1277~1288 (2015)[DOI]
- "FAQ-Cost for organ transplantation"[URL]
- "Organ transplant procedure"[URL]
- Cruz RJ, "Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: New trends and future opportunities", Surgery, 153(2), pp.150~159 (2013)[DOI]
- Jain A, "Long-term survival after liver transplantation in 4,000 consecutive patients at a single center", Ann Surg, 232(4), pp.490~500 (2000)[DOI]
- Levy AR, "The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons", Value Health, 11(3), pp.527~538 (2008)[DOI]
- Sakata H, "Cost analysis of adult-adult living donor liver transplantation in Tokyo University Hospital", J Hepatobiliary Pancreat Sci, 18(2), pp.184~189 (2011)[DOI]
- Serper M, "Functional status, healthcare utilization, and the costs of liver transplantation", Am J Transplant (2017)
- Thongsawat S, "Resource Utilization and Direct Medical Costs of Chronic Hepatitis C in Thailand: A Heavy but Manageable Economic Burden", Value in Health Regional Issues, 3, pp.12~18 (2014)[DOI]
- Kitazawa T, "Cost Analysis of Transplantation in Japan, Performed With the Use of the National Database", Transplant Proc, 49(1), pp.4~9 (2017)[DOI]
- "Medical Price Levels of OECD Countries: A Comparative Study: KMA Research Institute for Healthcare Policy"[URL]
- Abergel A, "Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study)", Clin Res Hepatol Gastroenterol, 40(3), pp.340~348 (2016)[DOI]
- "Costing methods in Healthcare: NECA"[URL]
- 김혜린, "환자표본자료를 이용한 간경변증 환자의 의료이용 특성 및 의료비용 분석", 한국임상약학회지, 26(4), pp.341~347 (2016), 한국임상약학회
- Shon C, "The Economic Burden of Hepatitis A, B, and C in South Korea", Jpn J Infect Dis, 69(1), pp.18~27 (2016)[DOI]
- Chen GF, "Will Sofosbuvir", Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data, 2016, pp.11(6), e0155934~
- Chhatwal J, "Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection are Cost Saving", Clin Gastroenterol Hepatol, 15(6), pp.827~837 (2016)
- Virabhak S, "Cost-effectiveness of directacting antiviral regimen ombitasvir", paritaprevir, J Med Econ, pp.2016[DOI]